<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Science and Innovations in Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Science and Innovations in Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Наука и инновации в медицине</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2500-1388</issn><issn publication-format="electronic">2618-754X</issn><publisher><publisher-name xml:lang="en">FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">691247</article-id><article-id pub-id-type="doi">10.35693/SIM691247</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Oncology and radiotherapy</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Онкология, лучевая терапия</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Transmesenteric approach in the surgical treatment of left kidney cancer with venous tumor thrombus of Mayo levels 0–I</article-title><trans-title-group xml:lang="ru"><trans-title>Трансмезентериальный доступ в хирургическом лечении рака левой почки с опухолевым венозным тромбозом 0–I уровня</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-8365-7672</contrib-id><name-alternatives><name xml:lang="en"><surname>Mirzabekov</surname><given-names>Musabek K.</given-names></name><name xml:lang="ru"><surname>Мирзабеков</surname><given-names>М. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate Student of the Department of Radiology, Surgery and Oncology</p></bio><bio xml:lang="ru"><p>аспирант кафедры радиологии, хирургии и онкологии</p></bio><email>Musabek.mirzabekoff@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0589-7999</contrib-id><name-alternatives><name xml:lang="en"><surname>Shkolnik</surname><given-names>Mikhail I.</given-names></name><name xml:lang="ru"><surname>Школьник</surname><given-names>М. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Associate Professor, Chief Researcher, Professor of the Department of Radiology, Surgery and Oncology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, доцент, главный научный сотрудник, профессор кафедры радиологии, хирургии и онкологии</p></bio><email>shkolnik_phd@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5860-9076</contrib-id><name-alternatives><name xml:lang="en"><surname>Bogomolov</surname><given-names>Oleg A.</given-names></name><name xml:lang="ru"><surname>Богомолов</surname><given-names>О. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Senior Researcher, Associate Professor of the Department of Radiology, Surgery and Oncology</p></bio><bio xml:lang="ru"><p>канд. мед. наук, старший научный сотрудник, доцент кафедры радиологии, хирургии и онкологии</p></bio><email>urologbogomolov@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Granov Russian Research Center of Radiology and Surgical Technologies</institution></aff><aff><institution xml:lang="kk"></institution></aff><aff><institution xml:lang="pt"></institution></aff><aff><institution xml:lang="ru">ФГБУ «Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова» Минздрава России</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Granov Russian Research Center of Radiology and Surgical Technologies</institution></aff><aff><institution xml:lang="ru">ФГБУ «Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-10-26" publication-format="electronic"><day>26</day><month>10</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-11-10" publication-format="electronic"><day>10</day><month>11</month><year>2025</year></pub-date><volume>10</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>321</fpage><lpage>326</lpage><history><date date-type="received" iso-8601-date="2025-09-23"><day>23</day><month>09</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-10-23"><day>23</day><month>10</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Mirzabekov M.K., Shkolnik M.I., Bogomolov O.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Мирзабеков М.К., Школьник М.И., Богомолов О.А.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Mirzabekov M.K., Shkolnik M.I., Bogomolov O.A.</copyright-holder><copyright-holder xml:lang="ru">Мирзабеков М.К., Школьник М.И., Богомолов О.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://innoscience.ru/2500-1388/article/view/691247">https://innoscience.ru/2500-1388/article/view/691247</self-uri><abstract xml:lang="en"><p><bold>Aim</bold> – to evaluate the efficacy and safety an original transmesenteric approach for laparoscopic nephrectomy with thrombectomy in patients with left kidney cancer and venous tumor thrombus (levels 0–I according to the Mayo classification).</p> <p><bold>Material and methods. </bold>The study included 19 patients with histologically verified left kidney cancer who underwent laparoscopic nephrectomy with thrombectomy using a transmesenteric approach. Eleven patients had renal vein thrombus (Mayo level 0), and eight patients had thrombus extending into the inferior vena cava up to 2 cm from the renal vein orifice (Mayo level I). The following parameters were assessed: age, body mass index, operative time, intraoperative blood loss, hospital stay, and postoperative complications.</p> <p><bold>Results. </bold>All procedures were completed laparoscopically without conversion. The mean operative time was 125.8 ± 11.4 min, and the mean blood loss was 152.6 ± 62.9 ml. The mean hospital stay was 7.4 ± 0.6 days. No early or late complications were recorded. Operative time and blood loss were significantly lower compared to previously published series of laparoscopic and open procedures. Conclusion. The transmesenteric approach minimizes surgical trauma, reduces operative time and blood loss, and lowers the risk of complications while maintaining oncological radicality. The method can be recommended for widespread use in onco-urological practice.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель</bold> – oценить эффективность и безопасность оригинального трансмезентериального доступа при лапароскопической нефрэктомии с тромб-эктомией у пациентов с раком левой почки и опухолевым венозным тромбозом 0–I уровня по классификации Mayo.</p> <p><bold>Материал и методы. </bold>В исследование включены 19 пациентов с верифицированным раком левой почки, которым выполнена лапароскопическая нефрэктомия с тромбэктомией трансмезентериальным доступом. У 11 больных выявлен тромб, ограниченный почечной веной (0 уровень по Mayo), у 8 – распространение тромба в нижнюю полую вену до 2 см от устья почечной вены (I уровень). Оценивались возраст, индекс массы тела, продолжительность операции, объем кровопотери, длительность госпитализации, наличие осложнений.</p> <p><bold>Результаты</bold>. Все вмешательства завершены лапароскопически, конверсий не потребовалось. Средняя продолжительность операции составила 125,8 ± 11,4 мин, средний объем кровопотери – 152,6 ± 62,9 мл. Средняя длительность госпитализации составила 7,4 ± 0,6 суток. Ранних и поздних осложнений в исследуемой группе не зарегистрировано. Показатели длительности операции и кровопотери были достоверно ниже, чем в опубликованных сериях лапароскопических и открытых операций.</p> <p><bold>Заключение. </bold>Трансмезентериальный доступ позволяет минимизировать травматичность вмешательства, сократить продолжительность операции, снизить кровопотерю и риск осложнений при сохранении онкологической радикальности. Методика может быть рекомендована для широкого применения в онкоурологической практике.</p></trans-abstract><kwd-group xml:lang="en"><kwd>renal cell carcinoma</kwd><kwd>venous tumor thrombus</kwd><kwd>laparoscopic nephrectomy</kwd><kwd>thrombectomy</kwd><kwd>transmesenteric approach</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>почечно-клеточный рак</kwd><kwd>опухолевый венозный тромбоз</kwd><kwd>лапароскопическая нефрэктомия</kwd><kwd>тромбэктомия</kwd><kwd>трансмезентериальный доступ</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Veronese N, Custodero C, Cella A, et al. Prevalence of multidimensional frailty and pre-frailty in older people in different settings: A systematic review and meta-analysis. Ageing Res Rev. 2023;92:101874. DOI: 10.1016/j.arr.2021.101498</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. DOI: 10.3322/caac.21834</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kaprin AD, Starinsky VV, Petrova GV, et al. Malignant neoplasms in Russia in 2021 (morbidity and mortality). M., 2022. (In Russ.). [Каприн А.Д., Старинский В.В., Петрова Г.В., и др. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). M., 2022]. URL: https://glavonco.ru/cancer_register/MT_2021.pdf</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma. European Urology. 2019;75(1):74-84. DOI: 10.1016/j.eururo.2018.08.036</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>World Cancer Research Fund. Kidney cancer statistics. World Cancer Research Fund International. 2022. URL: https://www.wcrf.org/preventing-cancer/cancer-statistics/kidney-cancer-statistics/</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Zhuo Liu, Xun Zhao, Liyuan Ge, et al. Completely laparoscopic versus open radical nephrectomy and infrahepatic tumor thrombectomy: Comparison of surgical complexity and prognosis. Asian Journal of Surgery. 2021;44(4):641-648. DOI: 10.1016/j.asjsur.2020.12.003</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Altinay M, Oba S. Predictors of mortality in elderly patients in emergency abdominal surgery: a retrospective single-center study. J Surg Med. 2023;7(10):646-650. DOI: 10.28982/josam.7972</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Marahanumaiah S, Suresh N, Rajkumar B, et al. Impact of obesity on surgical outcomes in patients undergoing emergency laparotomy: a prospective observational study. Cureus. 2025;17(6):e85887. DOI: 10.7759/cureus.85887</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lardas M, Stewart F, Scrimgeour D, et al. Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. European Association of Urology. 2016;70(2):265-80. DOI: 10.1016/j.eururo.2015.11.034</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Volkova MI, Vashakmadze NL, Klimov AV, et al. Prognosis of patients operated on for renal cell carcinoma and tumor venous thrombosis: experience of the Urology Clinics, N.N. Blokhin National Medical Research Center of Oncology. Cancer Urology. 2021;17(3):19-28. [Волкова М.И., Вашакмадзе Н.Л., Климов А.В., и др. Прогноз у пациентов, оперированных по поводу почечно-клеточного рака и опухолевого венозного тромбоза: опыт работы урологических клиник НМИЦ онкологии им. Н.Н. Блохина. Онкоурология. 2021;17(3):19-28]. DOI: 10.17650/1726-9776-2021-17-3-19-28</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mayo Clinic. Outcomes for patients with renal tumors and venous tumor thrombus. Mayo Clinic Professional. 2023. URL: https://www.mayoclinic.org/medical-professionals/urology/news/outcomes-for-patients-with-renal-tumors-and-venous-tumor-thrombus/mac-20570379</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Chen Z, Zhang H, Liu H, et al. Outcomes of renal cell carcinoma with associated venous tumor thrombus: experience from a large cohort and short time span in a single center. BMC Cancer. 2021;21:766. DOI: 10.1186/s12885-021-08508-x</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. Journal of Urology. 2005;174(5):1759-1763. DOI: 10.1097/01.ju.0000177487.64651.3a</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Mirzabekov MK, Bogomolov OA, Shkolnik MI, et al. Comparative analysis of survival rates in patients with renal cell carcinoma and level I–II tumor thrombus of the renal vein and inferior vena cava undergoing open versus laparoscopic surgical treatment. Perm Medical Journal. 2025;42(4):105-114. [Мирзабеков М.К., Школьник М.И., Богомолов О.А., и др. Сравнительный анализ показателей выживаемости пациентов с почечно-клеточный раком и опухолевым тромбозом почечной и нижней полой вены I–II уровня, подвергшихся хирургическому лечению открытым и лапароскопическим доступом. Пермский медицинский журнал. 2025;42(4):105-114]. DOI: 10.17816/pmj424105-114</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Nosov АК, Lushina PA. Kidney cancer incidence and mortality in Russia and Saint-Petersburg. Siberian journal of oncology. 2017;16(5):95-103. [Носов А.К., Лушина П.А. Анализ заболеваемости и смертности от рака почки в России и Санкт-Петербурге. Сибирский онкологический журнал. 2017;16(5):95-103]. DOI: 10.21294/1814-4861-2017-16-5-95-103</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Davydov MI, Matveev VB, Volkova MI, et al. Surgical treatment of renal cell carcinoma with advanced tumor invasion of the inferior vena cava. Cancer Urology. 2017;13(1):27-36. [Давыдов М.И., Матвеев В.Б., Волкова М.И., и др. Хирургическое лечение почечно-клеточного рака с инвазией в нижнюю половую вену. Онкоурология. 2017;13(1):27-36. DOI: 10.17650/1726-9776-2017-13-1-27-36</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Atduev VA, Amoev ZV, Danilov AA, et al. Surgical treatment of kidney cancer with extended inferior vena cava thrombi: complications and long-term results. Cancer Urology. 2017;13(1):37-44. [Атдуев В.А., Амоев З.В., Данилов А.А., и др. Хирургическое лечение рака почки с протяженными тромбами нижней полой вены: осложнения и отдаленные результаты. Онкоурология. 2017;13(1):37-44]. DOI: 10.17650/1726-9776-2017-13-1-37-44</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Campi R, Tellini R, Sessa F, et al. Techniques and outcomes of minimally-invasive surgery for nonmetastatic renal cell carcinoma with inferior vena cava thrombosis: a systematic review of the literature. Minerva Urol Nefrol. 2019;71(4):339-358. DOI: 10.23736/S0393-2249.19.03396-4</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Dell’Oglio P, Tappero S, Mandelli G, et al. Surgical and oncological outcomes of level III–IV versus level I–II inferior vena cava thrombectomy: A decennial experience of a high-volume European Referral Center. Annals of Surgical Oncology. 2024;31(12):8383-8393. DOI: 10.1245/s10434-024-15878-6</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Rose KM, Navaratnam AK, Faraj KS, et al. Comparison of Open and Robot-Assisted Radical Nephrectomy with Level I and II Inferior Vena Cava Tumor Thrombus: The Mayo Clinic Experience. Urology. 2020;136:152-157. DOI: 10.1016/j.urology.2019.11.002</mixed-citation></ref></ref-list></back></article>
